Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Pediatr Blood Cancer. 2013 Aug;60(8):E63-6. doi: 10.1002/pbc.24518. Epub 2013 Apr 1.
BAX/BCL2 ratio in pediatric AML has not been evaluated. In this first prospective study, we evaluated BAX/BCL2 transcript and RMFI ratio in 64 patients using real-time PCR (TaqMan Probe chemistry) and flow-cytometry, respectively. There was no correlation of BAX/BCL2 transcript ratio with RMFI ratio (R = -0.05; P = 0.715). Patients with WBC count >50,000/mm(3) had lower BAX/BCL2 RMFI ratio (P = 0.043), whereas no difference in ratio was observed among patients of different cytogenetics subgroups (P = 0.786). Higher BAX/BCL2 RMFI ratio was associated positively with CR rate (P = 0.03), but this study was unable to show that it translated into improved EFS or OS.
BAX/BCL2 比值在儿科急性髓细胞白血病（AML）中的作用尚未得到评估。在这项首次前瞻性研究中，我们使用实时 PCR（TaqMan 探针化学法）和流式细胞术分别评估了 64 例患者的 BAX/BCL2 转录本和 RMFI 比值。BAX/BCL2 转录本比值与 RMFI 比值之间无相关性（R = -0.05；P = 0.715）。白细胞计数（WBC）>50,000/mm(3)的患者 BAX/BCL2 RMFI 比值较低（P = 0.043），而不同细胞遗传学亚组的患者之间比值无差异（P = 0.786）。较高的 BAX/BCL2 RMFI 比值与完全缓解率（CR）呈正相关（P = 0.03），但本研究未能表明它转化为改善的无事件生存（EFS）或总生存（OS）。
